Martin Edwards is Director of REATA PHARMACEUTICALS INC. Currently has a direct ownership of 0 shares of RETA, which is worth approximately $0. The most recent transaction as insider was on Sep 26, 2023, when has been sold 6,116 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

Martin Edwards Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 26 2023
SELL
Sale (or disposition) back to the issuer
-
6,116 Reduced 100.0%
0 Class A Common Stock
Jun 07 2023
BUY
Grant, award, or other acquisition
$169,902 $93.61 p/Share
1,815 Added 22.88%
6,116 Class A Common Stock
Jun 08 2022
BUY
Grant, award, or other acquisition
$147,452 $34.76 p/Share
4,242 Added 49.65%
4,301 Class A Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
$1,612 $27.32 p/Share
59 Added 50.0%
59 Class A Common Stock

Also insider at

KALV
KalVista Pharmaceuticals, Inc. Healthcare
MORF
Morphic Holding, Inc. Healthcare
VRNA
Verona Pharma plc Healthcare
INZY
Inozyme Pharma, Inc. Healthcare
ME

Martin Edwards

Director
Plano, TX

Track Institutional and Insider Activities on RETA

Follow REATA PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RETA shares.

Notify only if

Insider Trading

Get notified when an Reata Pharmaceuticals Inc insider buys or sells RETA shares.

Notify only if

News

Receive news related to REATA PHARMACEUTICALS INC

Track Activities on RETA